Most recently, Gleason was VP of sales at Relievant, which was acquired by Boston Scientific for $850 million in September last year. He has also served as VP of sales of interventional urology at Teleflex and in other sales leadership roles at NeoTract before its acquisition by Teleflex in 2017.
“It is an honor to join Moximed as we expand access of the Misha Knee System to the many knee OA patients in the U.S. who may benefit,” Gleason said in a news release. “I have spoken to a number of patients, and I’m inspired by the amazing stories of how the Misha Knee System has positively impacted their lives. We have a talented team who is relentlessly dedicated to advancing patient care, and I look forward to helping Moximed realize its tremendous potential.”
Moximed develops the Misha Knee System for patients with medial knee OA who have not been able to find relief from previous treatments. It is an implantable shock absorber that reduces weight on the knee joint while walking. It is placed on the medial knee and moves with the natural joint, reducing about 30% of peak force on the knee, Moximed said.
“The Board enthusiastically welcomes Chris Gleason as our new CEO,” said Josh Makower, co-founder and chair of the board of directors at Moximed. “Moximed has a transformational, breakthrough product for the treatment of medial compartment knee osteoarthritis, and it is exciting to see Chris step in to lead this talented and resilient team towards the establishment of the MISHA Knee System as a new standard of care for patients suffering from this widespread condition.”
